Login to Your Account



ThromboGenics Sets January Launch as FDA Approves Jetrea

By Cormac Sheridan
Staff Writer

Friday, October 19, 2012

In an eagerly awaited milestone for the company – and for Belgian biotech – the FDA approved ThromboGenics NV's biologic drug Jetrea (ocriplasmin) for treating symptomatic vitreomacular adhesion (VMA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription